85
52
Growth Score
-6 pts
Heat Score
-21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
3145941
NIBR takes a unique approach to pharmaceutical research. At the earliest stages, patient need and disease determine research priorities.
Rachel Morgan: Global Head Clinical Sciences and InnovationPast Role: Novartis, Global Head Translational Medicine Scientific Operations
Jennifer Brogdon: Executive Director, Head of Cell Therapy Research, Exploratory Immuno-OncologyPast Role: Novartis Institutes, Director, Exploratory Immuno-Oncology
About the Company
NIBR takes a unique approach to pharmaceutical research. At the earliest stages, research priorities are determined by patient need and disease understanding.
At NIBR, physician-scientists are breaking down the boundaries between research and clinical practice.
They use Proof-of-Concept clinical trials (small-scale studies used to get an
early read on a drug’s safety and effectiveness) to help us find and advance the most promising drug candidates.
They believe they can better answer the demand for safer, more effective medicines by keeping our sights on both the science and the patient.
